Compositional dynamics of the human intestinal microbiota with aging: Implications for health

Journal of Nutrition, Health and Aging

Volumn 18, Issue 9, 2014, Pages 773-786

  Lakshminarayanan, B ^a,b   Stanton, C ^a,c   O'Toole P W ^b,c   Ross, R Paul ^a,c  

^a TEAGASC FOOD RESEARCH CENTRE   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

aging; Gastrointestinal tract; host health; microbiota

Indexed keywords

PREBIOTIC AGENT; PROBIOTIC AGENT; SYNBIOTIC AGENT; ANTIINFECTIVE AGENT;

AGED; AGING; ANTIBIOTIC ASSOCIATED DIARRHEA; ANTIBIOTIC THERAPY; ARTICLE; COLON CANCER; CROHN DISEASE; DIET; DYSBIOSIS; HUMAN; IMMUNOPATHOLOGY; INFANCY; INTESTINE; INTESTINE FLORA; IRRITABLE COLON; MICROBIAL DIVERSITY; MICROBIOME; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; SARCOPENIA; ULCERATIVE COLITIS; COLON TUMOR; DIABETES MELLITUS; DRUG EFFECTS; GERIATRICS; HEALTH; IMMUNOLOGY; MICROBIOLOGY; MICROFLORA; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGING; ANTI-BACTERIAL AGENTS; COLONIC NEOPLASMS; DIABETES MELLITUS; DIET; DYSBIOSIS; GERIATRICS; HEALTH; HUMANS; IMMUNE SYSTEM DISEASES; INTESTINES; MICROBIOTA; OBESITY; PREBIOTICS; PROBIOTICS; SYNBIOTICS;

EID: 84925284836     PISSN: 12797707     EISSN: 17604788     Source Type: Journal    
DOI: 10.1007/s12603-014-0549-6     Document Type: Article

References (225)

1. Savage DC. Microbial ecology of the gastrointestinal tract. Ann Rev Microbiol 1977; 31: 107–133.
2. Eckburg PB, Bik EM, Bernstein CN et al. Diversity of the human intestinal microbial flora. Science 2005; 308: 1635–1638.
3. Dethlefsen L, Eckburg PB, Bik EM et al. Assembly of the human intestinal microbiota. Trends Ecol Evol 2006; 21: 517–523.
4. Zoetendal EG, Vaughan EE, De Vos WM. A microbial world within us. Mol Microbiol 2006; 59: 1639–1650.
5. Rajilić-Stojanović M, Smidt H, De Vos WM. Diversity of the human gastrointestinal tract microbiota revisited. Environ Microbiol 2007; 9: 2125–2136.
6. Xu J, Mahowald MA, Ley RE et al. Evolution of Symbiotic Bacteria in the Distal Human Intestine. PLoS Biol 2007; 5: el56.
7. Qin J, Li R, Raes J et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59–65.
8. Guarner F, Malagelada J-R. Gut flora in health and disease. Lancet 2003; 361: 512–519.
9. Bäckhed F, Ley RE, Sonnenburg JL et al. Host-bacterial mutualism in the human intestine. Science 2005; 307: 1915–1920.
10. Stanton C, Ross RP, Fitzgerald GF et al. Fermented functional foods based on probiotics and their biogenic metabolites. Curr Opin Biotechnol 2005; 16: 198–203.
11. Medellin-Peña MJ, Griffiths MW. Effect of molecules secreted by Lactobacillus acidophilus strain La-5 on Escherichia coli 0157: H7 colonization. Appl Environ Microbiol 2009; 75: 1165–1172.
12. Bengmark S. Econutrition and health maintenance—a new concept to prevent GI inflammation, ulceration and sepsis. Clin Nutr 1996; 15: 1–10.
13. Greer JB, O’Keefe SJ. Microbial induction of immunity, inflammation, and cancer. Front Physiol 2010; 1: 168.
14. Zoetendal EG, Akkermans ADL, De Vos WM. Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl Environ Microbiol 1998; 64: 3854–3859.
15. Palmer C, Bik EM, DiGiulio DB et al. Development of the human infant intestinal microbiota. PLoS Biol 2007; 5: el77.
16. Blaut M, Clavel T. Metabolic diversity of the intestinal microbiota: implications for health and disease. J Nutr 2007; 137: 751S–755S.
17. Penders J, Thijs C, Vink C et al. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics 2006; 118: 511–521.
18. Dominguez-Bello MG, Costello EK, Contreras M et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A 2010; 107: 11971–11975.
19. Grölund M-M, Lehtonen O-P, Eerola E et al. Fecal microflora in healthy infants born by different methods of delivery: permanent changes in intestinal flora after cesarean delivery. J Ped Gastroenterol Nutr 1999; 28: 19–25.
20. Favier CF, Vaughan EE, De Vos WM et al. Molecular monitoring of succession of bacterial communities in human neonates. Appl Environ Microbiol 2002; 68: 219–226.
21. De Filippo C, Cavalieri D, Di Paola M et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A 2010; 107: 14691–14696.
22. Finegold SM, Sutter VL, Mathisen GE. Normal indigenous intestinal flora. Human intestinal microflora in health and disease 1983; 1: 3–31.
23. Delgado S, Suárez A, Mayo B. Identification of dominant bacteria in feces and colonic mucosa from healthy Spanish adults by culturing and by 16S rDNA sequence analysis. Dig Dis Sci 2006; 51: 744–751.
24. Ley RE, Hamady M, Lozupone C et al. Evolution of mammals and their gut microbes. Science 2008; 320: 1647–1651.
25. Larsen N, Vogensen FK, van den Berg FWJ et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 2010; 5: e9085.
26. Dethlefsen L, Huse S, Sogin ML et al. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008; 6: e280.
27. Holdeman LV, Good IJ, Moore WE. Human fecal flora: variation in bacterial composition within individuals and a possible effect of emotional stress. Appl Environ Microbiol 1976; 31: 359–375.
28. Hickson M. Malnutrition and ageing. Postgrad Med J 2006; 82: 2–8.
29. Lovat LB. Age related changes in gut physiology and nutritional status. Gut 1996; 38: 306–309.
30. Gavini F, Cayuela C, Antoine J-M et al. Differences in the distribution of bifidobacterial and enterobacterial species in human faecal microflora of three different (children, adults, elderly) age groups. Microb Ecol Health Dis 2001; 13: 40–45.
31. Claesson MJ, Cusack S, O’Sullivan O et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A 2011; 108:4586–4591.
32. Woodmansey EJ. Intestinal bacteria and ageing. J Appl Microbiol 2007; 102: 1178–1186.
33. Hopkins MJ, Macfarlane GT. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J Med Microbiol 2002;51:448–454.
34. Collino S, Montoliu I, Martin F-PJ et al. Metabolic Signatures of Extreme Longevity in Northern Italian Centenarians Reveal a Complex Remodeling of Lipids, Amino Acids, and Gut Microbiota Metabolism. PLoS One 2013; 8: e56564.
35. Bartosch S, Fite A, Macfarlane GT et al. Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using realtime PCR and effects of antibiotic treatment on the fecal microbiota. Appl Environ Microbiol 2004; 70: 3575–3581.
36. Biagi E, Nylund L, Candela M et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One 2010; 5: el0667.
37. Claesson MJ, Jeffery IB, Conde S et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012; 488: 178–184.
38. Tiihonen K, Ouwehand AC, Rautonen N. Human intestinal microbiota and healthy ageing. Ageing Res Rev 2010; 9: 107–116.
39. Hopkins MJ, Sharp R, Macfarlane GT. Age and disease related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance, and community cellular fatty acid profiles. Gut 2001; 48: 198–205.
40. Mariat D, Firmesse O, Levenez F et al. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol 2009; 9: 123.
41. Tiihonen K, Tynkkynen S, Ouwehand A et al. The effect of ageing with and without non-steroidal anti-inflammatory drugs on gastrointestinal microbiology and immunology. Br J Nutr 2008; 100: 130–137.
42. Rea MC, O’Sullivan O, Shanahan F et al. Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol 2012; 50: 867–875.
43. He F, Ouwehand AC, Isolauri E et al. Differences in composition and mucosal adhesion of bifidobacteria isolated from healthy adults and healthy seniors. Curr Microbiol 2001; 43: 351–354.
44. Mäkivuokko H, Tiihonen K, Tynkkynen S et al. The effect of age and non-steroidal anti-inflammatory drugs on human intestinal microbiota composition. Br J Nutr 2010; 103: 227–234.
45. Mueller S, Saunier K, Hanisch C et al. Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. Appl Environ Microbiol 2006; 72: 1027–1033.
46. Hayashi H, Sakamoto M, Kitahara M et al. Molecular analysis of fecal microbiota in elderly individuals using 16S rDNA library and T-RFLP. Microbiol Immunol 2003; 47:557–570.
47. Zwielehner J, Liszt K, Handschur M et al. Combined PCR-DGGE fingerprinting and quantitative-PCR indicates shifts in fecal population sizes and diversity of Bacteroides, bifidobacteria and Clostridium cluster IV in institutionalized elderly. Exp Gerontol 2009; 44: 440–446.
48. Benno Y, Endo K, Mizutani T et al. Comparison of fecal microflora of elderly persons in rural and urban areas of Japan. Appl Environ Microbiol 1989; 55: 1100–1105.
49. Manichanh C, Rigottier-Gois L, Bonnaud E et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut 2006; 55: 205–211.
50. Sokol H, Seksik P, Furet JP et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009; 15: 1183–1189.
51. Sekirov I, Russell SL, Antunes LCM et al. Gut microbiota in health and disease. Physiol Rev 2010; 90: 859–904.
52. Galdeano CM, Perdigon G. The probiotic bacterium Lactobacillus casei induces activation of the gut mucosal immune system through innate immunity. Clin Vaccine Immunol 2006; 13: 219–226.
53. Candela M, Perna F, Carnevali P et al. Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: Adhesion properties, competition against enteropathogens and modulation of IL-8 production. Intl J Food Microbiol 2008; 125: 286–292.
54. Maslowski KM, Mackay CR. Diet, gut microbiota and immune responses. Nature Immunol 2010; 12: 5–9.
55. Fukuda S, Toh H, Hase K et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 2011; 469: 543–547.
56. Collins SM, Denou E, Verdu EF et al. The putative role of the intestinal microbiota in the irritable bowel syndrome. Dig Liver Dis 2009; 41: 850–853.
57. Son G, Kremer M, Hines IN. Contribution of gut bacteria to liver pathobiology. Gastroenterol Res Pract 2010; 2010: Article ID: 453563.
58. Frank DN, St Amand AL, Feldman RA et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 2007; 104: 13780–13785.
59. Lupton JR. Microbial degradation products influence colon cancer risk: the butyrate controversy. J Nutr 2004; 134: 479–482.
60. Uronis JM, Mühlbauer M, Herfarth HH et al. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One 2009; 4: e6026.
61. Kau AL, Ahem PP, Griffin NW et al. Human nutrition, the gut microbiome and the immune system. Nature 2011; 474: 327–336.
62. Smith MI, Yatsunenko T, Manary MJ et al. Gut Microbiomes of Malawian Twin Pairs Discordant for Kwashiorkor. Science 2013; 339: 548–554.
63. Ley RE, Turnbaugh PJ, Klein S et al. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022–1023.
64. Turnbaugh PJ, Hamady M, Yatsunenko T et al. A core gut microbiome in obese and lean twins. Nature 2008; 457: 480–484.
65. Thompson WG, Longstreth GF, Drossman DA et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45:II43–II47.
66. Agrawal A, Khan M, Whorwell P. Irritable bowel syndrome in the elderly: An overlooked problem? Dig Liver Dis 2009; 41: 721–724.
67. Bradley HK, Wyatt GM, Bayliss CE et al. Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome. J Med Microbiol 1987; 23: 29–32.
68. Chadwick VS, Chen W, Shu D et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterol 2002; 122: 1778–1783.
69. Madden JAJ, Hunter JO. A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics. Br J Nutr 2002; 88: s67–s72.
70. Mättö J, Maunuksela L, Kajander K et al. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome—a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 2006; 43: 213–222.
71. Jeffery IB, O’Toole PW, Öhman L et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012; 61: 997–1006.
72. Katz S, Feldstein R. Inflammatory bowel disease of the elderly: a wake-up call. Gastroenterol Hepatol 2008; 4: 337–347.
73. Ananthakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis 2009; 15: 182–189.
74. Aspinall Al, Meddings JB. Inflammatory Bowel Disease in the Elderly. Gastrointest Dis 2003.
75. Dicksved J, Halfvarson J, Rosenquist M et al. Molecular analysis of the gut microbiota of identical twins with Crohn’s disease. ISME J 2008; 2: 716–727.
76. Macfarlane S, Furrie E, Cummings JH et al. Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis. Clin Infect Dis 2004; 38: 1690–1699.
77. Mylonaki M, Langmead L, Pantes A et al. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 2004; 16: 775–778.
78. McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol 2008; 3: 563–578.
79. Conly JM. Clostridium difficile-associated diarrhea-The new scourge of the health care facility. Can J Infect Dis 2000; 11: 25–27.
80. Shek FW, Stacey BS, Rendell J et al. The rise of Clostridium difficile: the effect of length of stay, patient age and antibiotic use. J Hosp Infect 2000; 45: 235–237.
81. Song X, Bartlett JG, Speck K et al. Rising economic impact of Clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol 2008; 29: 823–828.
82. Bauer MP, Kuijper EJ, Van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15: 1067–1079.
83. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009; 22: 191–197.
84. Khan MR, Bari H, Zafar SN et al. Impact of age on outcome after colorectal cancer surgery in the elderly-a developing country perspective. BMC Surgery 2011; 11: 11–17.
85. Mongan J, Kalady MF, Peppone L et al. Management of colorectal cancer in the elderly. Clin Geriatr 2010; 18: 30–40.
86. Matasar MJ, Sundararajan V, Grann VR et al. Management of Colorectal Cancer in Elderly Patients. Drugs Aging 2004; 21: 113–133.
87. Moore WE, Moore LH. Intestinal floras of populations that have a high risk of colon cancer. Appl Environ Microbiol 1995; 61: 3202–3207.
88. Kingston DGI, Van Tassell RL, Wilkins TD. The fecapentaenes, potent mutagens from human feces. Chem Res Toxicol 1990; 3: 391–400.
89. Scanlan PD, Shanahan F, Clune Y et al. Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. Environ Microbiol 2008; 10: 789–798.
90. Sobhani I, Tap J, Roudot-Thoraval F et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One 2011; 6: el6393.
91. Villareal DT, Apovian CM, Kushner RF et al. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO. The Obesity Society. Am J Clin Nutr 2005; 82: 923–934.
92. Osher E, Stern N. Obesity in Elderly Subjects In sheep’s clothing perhaps, but still a wolf! Diabetes care 2009; 32: S398–S402.
93. Newman A. Obesity in Older adults. OJIN: Online J Issues Nurs 2009; 14.
94. Schwiertz A, Taras D, Schäfer K et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity 2010; 18: 190–195.
95. Duncan S, Lobley G, Holtrop G et al. Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes 2008; 32: 1720–1724.
96. Jumpertz R, Le DS, Turnbaugh PJ et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr 2011; 94: 58–65.
97. Horwath C, Kouris-Blazos A, Savige GS et al. Eating your way to a successful old age, with special reference to older women. Asia Pac J Clin Nutr 1999; 8: 216–225.
98. Meneilly GS. Diabetes in the elderly. Med Clin North Am 2006; 90: 909–923.
99. Meneilly GS, Tessier D. Diabetes in elderly adults. J Gerontol 2001; 56A: M5–M13.
100. Sue Kirkman M, Briscoe VJ, Clark N et al. Diabetes in older adults: a consensus report. J Am Geriatr Soc 2012; 60: 2342–2356.
101. Qin J, Li Y, Cai Z et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012; 490: 55–60.
102. Almeida J, Galhenage S, Yu J et al. Gut flora and bacterial translocation in chronic liver disease. World J Gastroenterol 2006; 12: 1493–1502.
103. Campillo B, Richardet J-P, Kheo T et al. Nosocomial spontaneous bacterial peritonitis and bacteremia in cirrhotic patients: impact of isolate type on prognosis and characteristics of infection. Clin Infect Dis 2002; 35: 1–10.
104. De Palma G, Nadal I, Collado MC et al. Effects of a gluten-free diet on gut microbiota and immune function in healthy adult human subjects. Br J Nutr 2009; 102: 1154–1160.
105. Sanz Y. Effects of a gluten-free diet on gut microbiota and immune function in healthy adult humans. Gut Microbes 2010; 1: 135–137.
106. Vaahtovuo J, Munukka E, KorkeamÄKi M et al. Fecal microbiota in early rheumatoid arthritis. J Rheumatol 2008; 35: 1500–1505.
107. Biagi E, Candela M, Turroni S et al. Ageing and gut microbes: perspectives for health maintenance and longevity. Pharmacol Res 2012.
108. Cawthon PM, Marshall LM, Michael Y et al. Frailty in older men: prevalence, progression, and relationship with mortality. Journal of the American Geriatrics Society 2007; 55: 1216–1223.
109. Cawthon PM, Marshall LM, Michael Y et al. Frailty in older men: prevalence, progression, and relationship with mortality. J Am Geriatr Soc 2007; 55: 1216–1223.
110. Espinoza S, Walston JD. Frailty in older adults: insights and interventions. Cleve Clin J Med 2005; 72: 1105–1112.
111. Myers JS. Factors associated with changing cognitive function in older adults: implications for nursing rehabilitation. Rehabil Nurs 2008; 33: 117–123; discussion 132.
112. Myers JS. Factors associated with changing cognitive function in older adults: Implications for nursing rehabilitation. Rehabil Nursing 2008; 33: 117–123.
113. Barnes DE, Cauley JA, Lui LY et al. Women who maintain optimal cognitive function into old age. J Am Geriatr Soc 2007; 55: 259–264.
114. Yamada M, Arai H, Yoshimura K et al. Nutritional supplementation during resistance training improved skeletal muscle mass in community-dwelling frail older adults. J Frailty Aging 2012; 1: 64–70.
115. Franceschi C. Inflammaging as a major characteristic of old people: can it be prevented or cured? Nutr Rev 2007; 65: S173–S176.
116. Larbi A, Fülöp T, Pawelec G. Immune receptor signaling, aging and autoimmunity. Adv Exp Med Biol 2008; 640: 312–324.
117. Ferrucci L, Corsi A, Lauretani F et al. The origins of age-related proinflammatory state. Blood 2005; 105: 2294–2299.
118. Harris TB, Ferrucci L, Tracy RP et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106: 506–512.
119. Lio D, Scola L, Crivello A et al. Inflammation, genetics, and longevity: further studies on the protective effects in men of IL-10-1082 promoter SNP and its interaction with TNF-α-308 promoter SNP. J Med Genet 2003; 40: 296–299.
120. DeVeale B, Brummel T, Seroude L. Immunity and aging: the enemy within? Aging Cell 2004; 3: 195–208.
121. Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol 2007; 211: 144–156.
122. Ostan R, Bucci L, Capri M et al. Immunosenescence and immunogenetics of human longevity. Neuroimmunomodulation 2008; 15: 224–240.
123. Malaguarnera L, Cristaldi E, Malaguarnera M. The role of immunity in elderly cancer. Crit Rev Oncol Hematol 2010; 74: 40–60.
124. Sansonetti PJ. To be or not to be a pathogen: that is the mucosally relevant question. Mucosal Immunol 2010; 4: 8–14.
125. Fujihashi K, Kiyono H. Mucosal immunosenescence: new developments and vaccines to control infectious diseases. Trends Immunol 2009; 30: 334–343.
126. Yeh S-S, Schuster MW. Geriatric cachexia: the role of cytokines. Am J Clin Nutr 1999; 70: 183–197.
127. Magrone T, Jirillo E. The interaction between gut microbiota and age-related changes in immune function and inflammation. Immun Ageing 2013; 10: 31.
128. Guigoz Y, Doré J, Schiffrin EJ. The inflammatory status of old age can be nurtured from the intestinal environment. Curr Opin Clin Nutr Metab Care 2008; 11: 13–20.
129. Ouwehand AC, Bergsma N, Parhiala R et al. Bifidobacterium microbiota and parameters of immune function in elderly subjects. FEMS Immunol Med Microbiol 2008; 53: 18–25.
130. Turnbaugh PJ, Ridaura VK, Faith JJ et al. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 2009;1:6–14.
131. van Tongeren SP, Slaets JP, Harmsen H et al. Fecal microbiota composition and frailty. Appl Environ Microbiol 2005; 71: 6438–6442.
132. Lesourd BM, Laisney C, Salvatore R et al. Decreased maturation of T-cell populations in the healthy elderly: Influence of nutritional factors on the appearance of double negative CD4-, CD8-, CD2+ cells. Arch Gerontol Geriatr 1994; 19: 139–154.
133. Allen LH. Causes of vitamin B12 and folate deficiency. Food Nutr Bull 2008; 29: 20–34.
134. Laurin D, Brodeur J-M, Bourdages J et al. Fibre intake in elderly individuals with poor masticatory performance. J Can Dent Assoc 1994; 60: 443–446.
135. Schindler JS, Kelly JH. Swallowing disorders in the elderly. Laryngoscope 2009; 112: 589–602.
136. Wald A. Constipation in elderly patients: Pathogenesis and management. Drugs Aging 1993; 3: 220–220.
137. Bosshard W, Dreher R, Schnegg J-F et al. The treatment of chronic constipation in elderly people: an update. Drugs Aging 2004; 21: 911–930.
138. Wu GD, Chen J, Hoffmann C et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011; 334: 105–108.
139. Ley RE, Bäckhed F, Turnbaugh P et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci US A 2005; 102: 11070–11075.
140. Bingham SA. High-meat diets and cancer risk. Proc Nutr Soc 1999; 58: 243–248.
141. Kumar D, Singh G, Singh M et al. Diet and Functional Foods in Treatment and Maintenance Therapy of Colon Disorders. J Appl Pharma Sci 2012; 2: 177–187.
142. Myers SP. The causes of intestinal dysbiosis: a review. Altera Med Rev 2004; 9: 180–197.
143. Birkett A, Muir J, Phillips J et al. Resistant starch lowers fecal concentrations of ammonia and phenols in humans. Am J Clin Nutr 1996; 63: 766–772.
144. Cummings JH, Hill MJ, Bone ES et al. The effect of meat protein and dietary fiber on colonic function and metabolism; II. Bacterial metabolites in feces and urine. Am J Clin Nutr 1979; 32: 2094–2101.
145. Kruis W, Forstmaier G, Scheurlen C et al. Effect of diets low and high in refined sugars on gut transit, bile acid metabolism and bacterial fermentation. Gut 1991; 32: 367–371.
146. Jernberg C, Löfmark S, Edlund C et al. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J 2007; 1: 56–66.
147. Nord CE, Edlund C. Ecological effects of antimicrobial agents on the human intestinal microflora. Microbial Ecol Health Dis 1991; 4: 193–207.
148. Jakobsson HE, Jernberg C, Andersson AF et al. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One 2010;5:e9836.
149. Jernberg C, Löfmark S, Edlund C et al. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiol 2010; 156: 3216–3223.
150. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 2011; 108: 4554–4561.
151. Donskey CJ, Hujer AM, Das SM et al. Use of denaturing gradient gel electrophoresis for analysis of the stool microbiota of hospitalized patients. J Microbiol Meth 2003; 54: 249–256.
152. Woodmansey EJ, McMurdo MET, Macfarlane GT et al. Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects. Appl Environ Microbiol 2004; 70: 6113–6122.
153. Rea MC, Sit CS, Clayton E et al. Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc Natl Acad Sci U S A 2010; 107: 9352–9357.
154. Rea MC, Dobson A, O’Sullivan O et al. Effect of broad-and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci U S A 2011; 108: 4639–4644.
155. Mathur S, Singh R. Antibiotic resistance in food lactic acid bacteria—a review. Int J Food Microbiol 2005; 105: 281–295.
156. Rodríguez-Julbe MC, Ramírez-Ronda CH, Arroyo E et al. Antibiotics in older adults. PR Health Sci J 2010; 23: 25–33.
157. Sjölund M, Wreiber K, Andersson DI et al. Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann Intern Med 2003; 139: 483–487.
158. Young VB, Schmidt TM. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J Clin Microbiol 2004; 42: 1203–1206.
159. Sullivan Å, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001; 1: 101–114.
160. Aseeri M, Schroeder T, Kramer J et al. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008; 103: 2308–2313.
161. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001; 182: 11S–18S.
162. Holt PR. Intestinal malabsorption in the elderly. Dig Dis 2007; 25: 144–150.
163. Black FO, Pesznecker SC. Vestibular ototoxicity. Clinical considerations. Otolaryngol Clin North Am 1993; 26: 713–736.
164. Millan J, Gleckman R. Selecting the right antibiotics for elderly patients. J Crit Illness 1997; 12: 590–598.
165. FAO/WHO. Evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Joint FAO/WHO Expert Consultation, Food and Agriculture Organisation of the United Nations. Córdoba. Argentina October 2001: 1–4.
166. Dunne C, Murphy L, Flynn S et al. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek 1999; 76: 279–292.
167. Malaguarnera G, Leggio F, Vacante M et al. Probiotics in the gastrointestinal diseases of the elderly. J Nutr Health Aging 2012; 16: 402–410.
168. Ocaña VS, Nader-Macías ME. Production of Antimicrobial Substances by Lactic Acid Bacteria II: screening bacteriocin-producing strains with probiotic purposes and characterization of a Lactobacillus bacteriocin. Methods Mol Biol 2004; 268: 347–353.
169. O’Shea EF, Gardiner GE, O’Connor PM et al. Characterization of enterocin-and salivaricin-producing lactic acid bacteria from the mammalian gastrointestinal tract. FEMS Microbiol Lett 2008; 291: 24–34.
170. Fooks LJ, Fuller R, Gibson GR. Prebiotics, probiotics and human gut microbiology. Int Dairy J 1999; 9: 53–61.
171. Gibson GR, Probert HM, Van Loo J et al. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr Res Rev 2004; 17: 259–275.
172. Cummings JH, Macfarlane GT, Englyst HN. Prebiotic digestion and fermentation. Am J Clin Nutr 2001; 73: 415s–420s.
173. Gorbach S, Chang T-W, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet 1987; 2: 1519.
174. Katz JA. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. J Clin Gastroenterol 2006; 40: 249–255.
175. Bergonzelli GE, Blum S, Brüssow H et al. Probiotics as a treatment strategy for gastrointestinal diseases? Digestion 2005; 72: 57–68.
176. Arunachalam K, Gill HS, Chandra RK. Enhancement of natural immune function by dietary consumption of Bifidobacterium lactis (HN019). Eur J Clin Nutr 2000; 54: 263–267.
177. Gill HS, Cross ML, Rutherfurd KJ et al. Dietary probiotic supplementation to enhance cellular immunity in the elderly. Br J Biomed Sci 2001; 58: 94–96.
178. Fang H, Elina T, Heikki A et al. Modulation of humoral immune response through probiotic intake. FEMS Immunol Med Microbiol 2006; 29: 47–52.
179. Ouwehand AC, Salminen S, Isolauri E. Probiotics: an overview of beneficial effects. Antonie Van Leeuwenhoek 2002; 82: 279–289.
180. Sood A, Midha V, Makharia GK et al. The probiotic preparation, VSL# 3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 1202–1209.
181. Gibson GR, Wang X. Regulatory effects of bifidobacteria on the growth of other colonic bacteria. J Appl Microbiol 1994; 77: 412–420.
182. Ahmed M, Prasad J, Gill H et al. Impact of consumption of different levels of Bifidobacterium lactis HN019 on the intestinal microflora of elderly human subjects. J Nutr Health Aging 2007; 11: 26–31.
183. Lahtinen SJ, Tammela L, Korpela J et al. Probiotics modulate the Bifidobacterium microbiota of elderly nursing home residents. Age 2009; 31: 59–66.
184. He F, Morita H, Ouwehand AC et al. Stimulation of the secretion of proinflammatory cytokines by Bifidobacterium strains. Microbiol Immunol 2002; 46: 781–785.
185. Marco ML, Pavan S, Kleerebezem M. Towards understanding molecular modes of probiotic action. Curr Opin Biotechnol 2006; 17: 204–210.
186. Pitkala KH, Strandberg TE, Finne-Soveri UH et al. Fermented cereal with specific bifidobacteria normalizes bowel movements in elderly nursing home residents. A randomized, controlled trial. J Nutr Health Aging 2007; 11: 305–311.
187. Chiang BL, Sheih YH, Wang LH et al. Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (Bifidobacterium lactis HN019): optimization and definition of cellular immune responses. Eur J Clin Nutr 2000; 54: 849–855.
188. Rampelli S, Candela M, Severgnini M et al. A probiotics-containing biscuit modulates the intestinal microbiota in the elderly. J Nutr Health Aging 2013; 17: 166–172.
189. Ouwehand AC, Lagström H, Suomalainen T et al. Effect of probiotics on constipation, fecal azoreductase activity and fecal mucin content in the elderly. Ann Nutr Metab 2002; 46: 159–162.
190. An HM, Baek EH, Jang S et al. Efficacy of Lactic Acid Bacteria (LAB) supplement in management of constipation among nursing home residents. Nutr J 2010; 9: 1–7.
191. Turchet P, Laurenzano M, Auboiron S et al. Effect of fermented milk containing the probiotic Lactobacillus casei DN-114001 on winter infections in free-living elderly subjects: a randomised, controlled pilot study. J Nutr Health Aging 2003; 7: 75–77.
192. Hamilton-Miller JMT. Probiotics and prebiotics in the elderly. Postgrad Med J 2004;80:447–451.
193. Gill HS, Rutherfurd KJ. Probiotic supplementation to enhance natural immunity in the elderly: effects of a newly characterized immunostimulatory strain Lactobacillus rhamnosus HN001 (DR20?) on leucocyte phagocytosis. Nutr Res 2001; 21: 183–189.
194. Gill HS, Rutherfurd KJ, Cross ML et al. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am J Clin Nutr 2001; 74: 833–839.
195. Ibrahim F, Ruvio S, Granlund L et al. Probiotics and immunosenescence: cheese as a carrier. FEMS Immunol Med Microbiol 2010; 59: 53–59.
196. Lahtinen SJ, Forssten S, Aakko J et al. Probiotic cheese containing Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus NCFM® modifies subpopulations of fecal lactobacilli and Clostridium difficile in the elderly. Age 2012; 34: 133–143.
197. Takeda K, Okumura K. Effects of a fermented milk drink containing Lactobacillus casei strain Shirota on the human NK-cell activity. J Nutr 2007; 137: 791S–793S.
198. Morimoto K, Takeshita T, Nanno M et al. Modulation of natural killer cell activity by supplementation of fermented milk containing Lactobacillus casei in habitual smokers. Prev Med 2005; 40: 589–594.
199. Guigoz Y, Rochat F, Perruisseau-Carrier G et al. Effects of oligosaccharide on the faecal flora and non-specific immune system in elderly people. Nutr Res 2002; 22: 13–25.
200. Kleessen B, Sykura B, Zunft H-J et al. Effects of inulin and lactose on fecal microflora, microbial activity, and bowel habit in elderly constipated persons. Am J Clin Nutr 1997; 65: 1397–1402.
201. Vulevic J, Drakoularakou A, Yaqoob P et al. Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers. Am J Clin Nutr 2008; 88: 1438–1446.
202. Bouhnik Y, Achour L, Paineau D et al. Four-week short chain fructo-oligosaccharides ingestion leads to increasing fecal bifidobacteria and cholesterol excretion in healthy elderly volunteers. Nutr J 2007; 6: 42.
203. Reyed M. The role of bifidobacteria in health. Res J Medicine Med Sci 2000; 2: 14–24.
204. Furrie E, Macfarlane S, Kennedy A et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active Ulcerative Colitis: a randomised controlled pilot trial. Gut 2005; 54: 242–249.
205. Fujimori S, Tatsuguchi A, Gudis K et al. High dose probiotic and prebiotic cotherapy for remission induction of active Crohn’s disease. J Gastroenterol Hepatol 2006; 22: 1199–1204.
206. Björklund M, Ouwehand AC, Forssten SD et al. Gut microbiota of healthy elderly NSAID users is selectively modified with the administration of Lactobacillus acidophilus NCFM and lactitol. Age 2012; 34: 987–999.
207. Ouwehand AC, Tiihonen K, Saarinen M et al. Influence of a combination of Lactobacillus acidophilus NCFM and lactitol on healthy elderly: intestinal and immune parameters. Br J Nutr 2009; 101: 367–375.
208. Bartosch S, Woodmansey EJ, Paterson JCM et al. Microbiological effects of consuming a synbiotic containing Bifidobacterium bifidum, Bifidobacterium lactis. and oligofructose in elderly persons, determined by real-time polymerase chain reaction and counting of viable bacteria. Clin infect Dis 2005; 40: 28–37.
209. Gopal PK, Prasad J, Gill HS. Effects of the consumption of Bifidobacterium lactis HN019 (DR10 sup TM/sup) and galacto-oligosaccharides on the microflora of the gastrointestinal tract in human subjects. Nutr Res 2003; 23: 1313–1328.
210. Srinivasan V, Maestroni G, Cardinali D et al. Melatonin, immune function and aging. Immun Ageing 2005; 2: 17.
211. McClean P, Hughes C, Tunney M et al. Antimicrobial prescribing in European nursing homes. J Antimicrob Chemother 2011; 66: 1609–1616.
212. Rodríguez-Julbe MC, Ramírez-Ronda CH, Arroyo E et al. Antibiotics in older adults. P R Health Sci J 2004; 23.
213. Chandler M, Toler S, Rapp R et al. Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients. Antimicrob Agents Chemother 1990; 34: 442–447.
214. Varoquaux O, Lajoie D, Gobert C et al. Pharmacokinetics of the trimethoprim-sulphamethoxazole combination in the elderly. Br J Clin Pharmacol 1985; 20: 575–581.
215. Mörike K, Schwab M, Klotz U. Use of aminoglycosides in elderly patients. Drugs Aging 1997; 10: 259–277.
216. Tursi A, Brandimarte G, Giorgetti GM et al. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol 2006; 40: 312–316.
217. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101: 812–822.
218. Fukushima Y, Miyaguchi S, Yamano T et al. Improvement of nutritional status and incidence of infection in hospitalised, enterally fed elderly by feeding of fermented milk containing probiotic Lactobacillus johnsonii La1 (NCC533). Br J Nutr 2007; 98: 969–977.
219. Hickson M, D’Souza AL, Muthu N et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007; 335: 80.
220. Sinn DH, Song JH, Kim HJ et al. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 2008; 53: 2714–2718.
221. Boge T, Rémigy M, Vaudaine S et al. A probiotic fermented dairy drink improves antibody response to influenza vaccination in the elderly in two randomised controlled trials. Vaccine 2009; 27: 5677–5684.
222. Ndagijimana M, Laghi L, Vitali B et al. Effect of a synbiotic food consumption on human gut metabolic profiles evaluated by sup 1/sup H Nuclear Magnetic Resonance spectroscopy. Int J Food Microbiol 2009; 134: 147–153.
223. Lamiki P, Tsuchiya J, Pathak S et al. Probiotics in diverticular disease of the colon: an open label study. J Gastrointestin Liver Dis 2010; 19: 31–36.
224. Guillemard E, Tondu F, Lacoin F et al. Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial. Br J Nutr 2010; 103: 58–68.
225. Namba K, Hatano M, Yaeshima T et al. Effects of Bifidobacterium longum BB536 administration on influenza infection, influenza vaccine antibody titer and cell-mediated immunity in the elderly. Biosci Biotechnol Biochem 2010; 74: 939–945.